Targeted therapeutics
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
1. A binding moiety-drug conjugate (SDC-TRAP) comprising a binding moiety and an effector moiety, wherein the SDC-TRAP is selected from the group consisting of
2. A pharmaceutical composition comprising a therapeutically effective amount of at least one SDC-TRAP of claim 1 or a salt thereof, and at least one pharmaceutical excipient.
3. A method of treating tumor in a subject in need thereof comprising administering the pharmaceutical composition of claim 2 to the subject, thereby treating the subject.
4. The method of claim 3 , wherein the tumor volume is reduced.
5. The method of claim 4 , wherein the tumor is colorectal cancer, breast cancer, small cell lung cancer, sarcoma, or pancreatic cancer.